Loading…
← CockpitCompetitor Analysis › LKFT.AS Lakefront BiotherapeuticsOpen in the cockpit ↗

Lakefront BiotherapeuticsLKFT.ASCompetitor analysis, valuation and peers

Netherlands · EUR·Health Care›Biotechnology

Belgian clinical-stage biotech (formerly Galapagos) developing immunology drugs, led by a BCMA/CD3 T-cell engager, with cell therapy being wound down.

Momentum leader 98
Mkt cap
$2.26B
US dollars, full cap
Free float
68%
of shares outstanding
$/day
$2.97M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+37.1 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
98 days
24 Feb 2027
Close · EUR€31.32
1D-0.5%
1W+5.1%
1M+15.2%
3M+25.7%
6M+31.4%
YTD+11.9%
1Y+18.0%
ATR %3.0%
52w lowhigh2.4% off high

What Lakefront Biotherapeutics does

Belgian clinical-stage biotech (formerly Galapagos) developing immunology drugs, led by a BCMA/CD3 T-cell engager, with cell therapy being wound down.

Has no product sales after selling its approved drug filgotinib to Alfasigma in 2024, so it lives off a large cash balance. It is rebuilding around autoimmune treatments: it took on Ouro Medicines' T-cell engager together with Gilead, its major shareholder, and is winding down cell-therapy operations. Renamed from Galapagos in 2026.

Products and services

  • Gamgertamig (BCMA/CD3 T-cell engager, autoimmune blood disor
  • GLPG3667 (TYK2 inhibitor, lupus; options under review)
  • Cell therapy platform (being wound down)

Customers

  • Hospitals and specialist physicians (post-approval
  • Gilead Sciences (collaboration partner and major s

Where it sits in the supply chain

  • Biotechnology
  • Clinical-stage drug development
  • Immunology: T-cell engager and small…

What could go right

  • Large cash balance funds the pipeline
  • Lead asset has FDA Fast Track and Orphan designations

What could go wrong

  • Lupus trial of GLPG3667 missed its main goal
  • No approved products and cash still being spent

Moat: narrow (IP / patents). Rights to a clinical-stage T-cell engager plus a large cash buffer; no approved products.

Headquarters: Mechelen, Belgium · Founded: 1999 · Employees: 452

Named competitors

Lakefront Biotherapeutics at a glance

Size Lakefront Biotherapeutics (LKFT.AS) is a Netherlands Health Care company (Biotechnology) with a market value of $2.26B, the 40th largest of 60 Netherlands companies the cockpit tracks. Shares closed at €31.32 on 18 Nov 2026.

Performance Over six months the shares gained 31.4%, against -10.8% for the median peer and -4.8% for the Netherlands market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 223.1% over the last twelve months (peer median +4.1%); the operating margin is 64.5% (peer median -19.9%).

Capital Return on invested capital runs 37.1 points above its cost of capital (5.0% WACC).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026LKFT.AS 129Peer median 92
Six months, rebased to 100: Lakefront Biotherapeutics against the median of its 20 peers (local-currency closes).

Lakefront Biotherapeutics financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€927M€1.11B€276M€240M€241M
Revenue growth—+304%+15%-1%—
Gross profit€909M€1.03B€192M€204M€211M
EBITDAn/a€522M-€179M-€91.9M-€102M
Net income€796M€321M€74.1M€212M-€218M
Free cash flow-€142M-€211M-€307M-€410M-€525M
Capital expenditure€1.91M€13.9M€82.1M€19.3M€36.9M
Total debt€3.10M€6.92M€11.7M€9.60M€21.9M

Quarterly statements and history in the cockpit →

Lakefront Biotherapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%RCUSVIMIAN302440PHVS300255BEAMCLDXZEALPVLA300676ALMRXNCRIMNMMBXMRVILKFT.AS6-month return →1-month return →
Up and to the right = strong over both horizons. Lakefront Biotherapeutics is the large dot.

Lakefront Biotherapeutics competitors and peer comparison

Head to head with its named competitors (LKFT.AS vs ARGX vs NOVN.SW vs AMGN)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Lakefront Biotherapeutics LKFT.AS$2.26B+31%+223%64%n/an/a
argenx SE Sponsored ADR ARGX$59.1B+17%+71%29%10.3×11.7%
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Amgen AMGN$240B+34%+9%36%7.2×1.6%
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%5.4×-1.1%

How Lakefront Biotherapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lakefront Biotherapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureLKFT.ASPeer medianRank in peer set
1-month return+15.2%-4.9%3rd highest of 21
6-month return+31.4%-10.8%6th highest of 20
Distance from 52-week high-2.4%-35.4%2nd highest of 21
Revenue growth (TTM)+223.1%+4.1%highest of 17
Operating margin64.5%-19.9%highest of 15
ROIC minus cost of capital+37.1 pp-11.0 pp2nd highest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%9,677.0×n/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%0.4×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a

Questions

Who are Lakefront Biotherapeutics's main competitors?
Named competitors: argenx (ARGX), Novartis (NOVN.SW), Amgen (AMGN), Regeneron (REGN). The cockpit's measured peer set (industry) also includes Arcus Biosciences (RCUS), Vimian (VIMIAN.ST), SKBS (302440.KS), Pharvaris (PHVS), Hebei Changshan Biochemical Pharmaceutical (300255.SZ), Beam Therapeutics (BEAM).
How has Lakefront Biotherapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +31.4% against -10.8% for the median peer; over one year +18.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.